Close Menu

NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Wednesday that its first quarter revenues rose 84 percent year over year, thanks largely to a 103 percent increase in testing services revenues.

For the three months ended March 31, the molecular diagnostics company reported total revenues of $26.0 million, up from $14.1 million during the same period a year earlier, and beating the average Wall Street analyst estimate of $24.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.